

**Remarks**


Applicants respectfully request that the presently amended claims be entered. Presently applicants cancel claim 2 and withdraw claim 16, without prejudice to the subject matter therein, reserving the right to pursue said withdrawn and cancelled claims in subsequently filed application(s). After entry of the present amendment claims 1, 3-8, and 11 remain in the application.

In the Communication dated July 22, 2009, restriction to one of two groups of inventions I-II was required as follows:

Group I claims 1, 3-8, 11 and 16, drawn to a compound structurally represented by Formula I, a method for treatment or prevention of obesity, and a composition including same.

Group II claim 2, drawn to a compound structurally represented by Formula II.

Further the above named communication also required further election of a single species for the elected Group. In response the Applicants elect without traverse the invention of Group I, claims 1, 3-8, 11 and 16, and further elect 6-Cyclopentyl amino-5,6,7,8-tetrahydro-naphthalen-2-yl)-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-methanone, which is shown structurally below, and found in Example 1 of the application.



Claims 1, 3, 5, 7, 8, and 11 read on the elected species.

Applicants request timely examination leading to allowance of all pending claims. The Examiner is invited to contact the undersigned attorney by telephone if the undersigned can be of any assistance.

Respectfully submitted,

/Dan L. Wood/  
Dan L. Wood  
Attorney/Agent for Applicant(s)  
Registration No. 48,613  
Phone: 317-277-3366

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
August 24, 2009